摘要
G蛋白偶联受体激酶有多个亚型,参与多种疾病的发生发展,其中G蛋白偶联受体激酶2(GRK2)在压力负荷诱导的心肌肥厚的调控中起重要作用。心肌肥厚是心力衰竭的早期病理学改变,目前临床上对心力衰竭监测常用的生物标志为氨基末端脑钠肽前体,其监测心血管不良事件与GRK2相比相对较晚。GRK2结构特点及在心肌肥厚调控中的机制使其有望成为监测心肌肥厚的潜在生物标志,临床上可通过监测患者外周血淋巴细胞GRK2 mRNA的表达水平对早期心肌肥厚进行有效干预或者后期GRK2与传统生物标志合用以提高对心力衰竭的诊治率。
G protein-coupled receptor kinases（ GRK） have many isoforms,and participate in a variety of development and incidence of diseases. G protein coupled receptor kinase 2 belongs to the GRK families,and takes part in the regulation of cardiomyopathy induced by pressure-overload. Cardiomyopathy is an early pathological change in heart failure（ HF）. At present,the most commonly used biological marker for monitoring HF in the clinic is amino terminal brain natriuretic peptide precursor（ NT-pro BNP）. It is possible to use NT-pro BNP to detect adverse cardiovascular events in late stages of cardiomyopathy whereas it is possible to use GRK2 to identify cardiomyopathy in its early stages. GRK2 may be used as a potential biomarker for its structural characteristics and regulatory mechanisms in cardiomyopathy. It can not only be used to effectively identify cardiomyopathy in the early stages by monitoring the expression of the mRNA of GRK2 in peripheral lymphocyte of patients in clinic,but it can also be used to enhance the efficiency of the diagnosis and treatment of HF.
出处
《心血管病学进展》
CAS
2015年第1期34-37,共4页
Advances in Cardiovascular Diseases
基金
教育部博士点基金(优先发展领域)-(2013041130010)
